Arax Advisory Partners’s Haemonetics HAE Stock Holding History

Arax Advisory Partners’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.5K	Sell	133 -127	-49%	-$8.27K	﹤0.01%	2597
2025 Q4	$20.8K	Sell	260 -10,153	-98%	-$682K	﹤0.01%	2088
2025 Q3	$508K	Buy	10,413 +9,789	+1,569%	+$606K	0.01%	895
2025 Q2	$46.6K	Buy	624 +609	+4,060%	+$40.3K	﹤0.01%	1274
2025 Q1	$954	Buy	15 +6	+67%	+$408	﹤0.01%	2316
2024 Q4	$703	Sell	9 -30	-77%	-$2.41K	﹤0.01%	2248
2024 Q3	$3.13K	Hold	39	–	–	﹤0.01%	1905
2024 Q2	$3.23K	Buy	+39	New	+$3.43K	﹤0.01%	1793
2023 Q4	–	Sell	-7	Closed	-$628	–	1377
2023 Q3	$628	Sell	7 -13	-65%	-$1.16K	﹤0.01%	1214
2023 Q2	$1.7K	Sell	20 -18	-47%	-$1.52K	﹤0.01%	1028
2023 Q1	$3.15K	Buy	38 +25	+192%	+$2.02K	﹤0.01%	942
2022 Q4	$1.02K	Hold	13	–	–	﹤0.01%	1067
2022 Q3	$1K	Buy	+13	New	+$933	﹤0.01%	1081

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arax Advisory Partners's HAE Position: Q1 2026 in Review

Arax Advisory Partners reduced its Haemonetics (HAE) stake by 49% in Q1 2026, selling an estimated $8.27K and leaving 133 shares worth $7.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2597.

Arax Advisory Partners first reported a position in HAE in Q3 2022 and has held it in 13 quarters since. The position peaked at $508K in Q3 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

Arax Advisory Partners held 133 shares of Haemonetics worth $7.5K as of Q1 2026.
Arax Advisory Partners sold 127 Haemonetics shares in Q1 2026, an estimated $8.27K.
Haemonetics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #2597 holding.
Arax Advisory Partners first reported a position in Haemonetics in Q3 2022 and has held it in 13 quarters since.
Arax Advisory Partners's Haemonetics position peaked at $508K in Q3 2025.
324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.